Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

Simonaggio, Audrey; Michot, Jean‐Marie; Laure Voisin, Anne; Le Pavec, Jérôme; Collins, Michael; Lallart, A.; Cengizalp, Geoffray; Vozy, Aurore; Laparra, Ariane; Varga, Andréa; Hollebecque, Antoine; Champiat, Stéphane; Marabelle, Aurélien; Massard, Christophe; Lambotte, Olivier

doi:10.1001/jamaoncol.2019.1022

Public

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

Published in JAMA Oncology • Jun 6, 2019

Authors:

Audrey Simonaggio

Jean‐Marie Michot

Anne Laure Voisin

Abstract

IMPORTANCE: Although immune checkpoint inhibitors (ICIs), such as anti-PD-1 (programmed cell death 1) or anti-PD-L1 (programmed cell death 1 ligand 1), have proved effective in treating many cancers, patients receiving ICIs may experience immune-related adverse events (irAEs). Little evidence exists...

Subject

Medicine

Pneumonitis

Adverse effect

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!